BioVie Announces Efficacy Data from Phase 3 Trial of
Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker...
Source: globenewswire.com
Page 2 - Suzanne Hendrix News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Suzanne Hendrix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Suzanne Hendrix Today - Breaking & Trending Today
BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer's Disease
29.11.2023 - Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker Endpoints Sponsor Identified Issues Relating to Significant GCP Violations and Protocol ...
Source: wallstreet-online.de
MRI Data Suggest Simufilam is Not Associated with
Safety Finding Based on Blinded MRI Brain Data at Week 40ARIA is a Known Risk Factor for Anti-Amyloid Antibody DrugsMRI Data Presented at the 16th CTAD...
Source: globenewswire.com
Oral Simufilam Slowed Cognitive Decline in a Randomized
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild...
Source: globenewswire.com
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer's Disease
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild Alzheimer’s Disease.In Mild...
Source: marketscreener.com